The clinical management of inoperable endometrial carcinoma

Marguerite Palisoul, David G. Mutch

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


ABSTRACT: Unresectable endometrial cancer, while rare, has a very poor prognosis, with a survival rate of 2 to 8 months. Although endometrial cancer is generally regarded as a survivable disease, the less common advanced and aggressive forms account for a large portion of endometrial cancer related deaths. Given the paucity of inoperable disease, randomized clinical data is lacking in this specific patient population. Management decisions regarding radiation therapy or systemic therapy are largely guided by the existing data in the setting of recurrence or second-line treatment, adjuvant therapy following optimal debulking, or in patients who are considered inoperable due to medical comorbidities rather than the extent of their disease.

Original languageEnglish
Pages (from-to)515-521
Number of pages7
JournalExpert Review of Anticancer Therapy
Issue number5
StatePublished - May 3 2016


  • Inoperable endometrial cancer
  • bevacizumab
  • carboplatin
  • medroxyprogesterone acetate
  • megestrol acetate
  • paclitaxel
  • palliation
  • temsirolimus
  • tumor-directed radiation


Dive into the research topics of 'The clinical management of inoperable endometrial carcinoma'. Together they form a unique fingerprint.

Cite this